CD21
Use
CD21 is a transmembrane receptor present on mature B-cells and follicular dendritic cells. It binds the C3d fragment of the complement system as well as Epstein Barr virus (EBV) and HHV8. CD21 antigen has been reported in B-cell chronic lymphocytic leukemias, a subset of T-cell acute lymphocytic leukemias, follicular/mantle cell lymphomas, and mature leukemias/lymphomas.
Special Instructions
Fresh Tissues: Specimens may be fixed in formalin for 24-72 hours by collection sites, then transferred to 70% ethanol and stored at 2-8°C for longer term storage if needed. Samples must be tested 3 months after placing in ethanol. Unstained slides: Positively charged glass slides required to prevent background staining and prevent tissue loss. Slides should be left unbaked.
Limitations
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Methodology
Immunoassay (IHC)
Biomarkers
Result Turnaround Time
2 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (Fresh)
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Fixative should be at a 20:1 fixative to tissue ratio, 10% neutral buffered formalin (NBF) for 6-72 hours (48-72 hours PREFERRED).
Storage Instructions
Specimens may be transferred to 70% alcohol for transportation purposes after fixation in 10% NBF or B plus.
Causes for Rejection
Specimens must be fixed in 10% NBF or B plus. All other fixatives will be rejected.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | ≤ 72 Hours |